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Cystinuria is an autosomal recessive genetic disorder characterized by the 
defect of a renal transporter involved in cystine reabsorption.  When this 
transporter is deficient, cystine cannot be broken down and reabsorbed by the 
body and is excreted via urine in high concentrations.  The high levels of cystine 
present in the urine eventually lead to recurrent cystine urolithiasis due to its 
inability to solubilize.  Despite having various forms of treatments such as thiol 
pharmaceutical therapies such as tiopronin and urine alkalinizing agents like 
potassium citrate, only few patients with cystinuria are able to successfully 
decrease cystine urine concentration.  We observed the effects of tiopronin on its 
ability to inhibit and prevent stone formation and found it to be only moderately 
effective.  In addition to observing tiopronin as a therapeutic, we also looked into 
the effects of potassium citrate as a treatment.  We found potassium citrate to 
have a varying effects on both urinary pH and stone formation.  Recently, our lab 
had shown that the nutritional-supplement α lipoic acid was an effective inhibitor 
of cystine stone formation. Here, we continued to further confirm the effects of α 
lipoic acid as an inhibitor and preventer of stone growth.  Due to the unknown 
mechanism of α lipoic acid, we hypothesized α lipoic acid to be promoting 
cystine reabsorption through the Nrf2 pathway.  In our Slc3a1-/-; Nrf2-/- mouse 
model, the mice treated with α lipoic acid still continued to have a reduced rate of 
stone formation.  These results suggested Nrf2 was not the pathway in which α 
lipoic acid was inhibiting stone growth. In addition, we observed the effects of the 
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combination of potassium citrate and α lipoic acid since potassium citrate is a 
standard of care of cystinuric patients.  Our results suggested there are no adverse 


























• The commonly used thiol therapeutic for cystinuria patients, tiopronin 
(TIO), was shown to significantly decrease the rate of stone growth in the 
Slc3a1-/- mouse model.  However, the therapeutic was observed not to be 
an effective stone formation preventer. 
• Potassium citrate (KCIT), an alkalinizing agent and a therapeutic that is a 
part of the standard of care for all cystinuric patients, had varying effects 
on stone formation and did not successfully alkalinize urinary pH. 
• Zee et al. recently reported the thiol antioxidant, α lipoic acid, to be an 
effective inhibitor of cystine stone growth and inhibition.  Our results 
further confirmed this finding. 
• Nrf2, a transcription factor that mediates antioxidant response element 
genes, was the hypothesized pathway α lipoic acid worked through to 
inhibit stone growth.  However, results with the Slc3a1-/-; Nrf2-/- mouse 
model indicate this was not the mechanism LA worked through to induce 
cystine stone inhibition in the Slc3a1-/- mouse. 
• The administration of potassium citrate and α lipoic acid in conjunction 
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Fig. 1 – Thesis overview.  Three therapeutics: tiopronin, potassium citrate, and α 
lipoic acid were administered to the cystinuric, Slc3a1-/- mouse model. The mice 
were scanned on a weekly basis in order to track in vivo stone growth. The 
combination of potassium citrate and α lipoic acid were administered to observe 
the effects of the two drugs may have on one another.  A Slc3a1-/-; Nrf2-/- mouse 
model was administered α lipoic acid to observe the role the Nrf2 pathway 
played in α lipoic acid’s ability to induce stone rate inhibition.  







Kidney Stone Disease is an Increasing Public Health Problem 
 
Over the last 25 years, the prevalence of kidney stone formation has risen 
in the U.S. and affects approximately 9% of adult American regardless of sex or 
ethnicity (Arumuham & Bycroft, 2016; Scales, Smith, Hanley, & Saigal, 2012).  
This rise has been speculated to be caused by change of active lifestyles to 
sedentary ones and diet.  Risk factors of stone formation generally include 
obesity, diabetes, and certain metabolic syndromes such as gout.  Stone formers 
are at risk for hypertension, chronic kidney disease, and end-stage renal disease 
(Khan et al., 2016).   Although males have traditionally had higher incidences of 
stone cases, recently females have been observed to have increased prevalence of 
stone formation.  The possible reason behind this rise in stone incidences in 
females is the increasing obesity rates amongst both males and females 
(Arumuham & Bycroft, 2016; Khan et al., 2016).  There are five types of kidney 
stones.  Calcium oxalate is the most common stone type making up 80% of cases 
meanwhile other forms of stones such as calcium phosphate, uric acid, struvite, 
and cystine are respectively 5%, 9%, 8%, and 1% of stone incidences.  
Idiopathic hypercalciuria patients make up 50% of calcium stone formers.  
This is a medical condition in which there is an increased excretion of calcium 
present in the body despite the lack of any diseases that could play a role in these 
elevated levels.  There are certain systemic diseases such as primary 
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hyperparathyroidism and renal tubular acidosis that contributes to abnormal levels 
of calcium present in the blood.  These conditions can lead or cause the patient to 
be at risk for calcium stone formation, but the majority of calcium based stone 
formers are idiopathic hypercalciuria patients (Coe, Worcester, & Evan, 2016; 
Khan et al., 2016; Worcester & Coe, 2008).  Generally, patients with 
hypercalciuria excrete approximately over 300 mg of calcium per day 
(Lewandowski & Rodgers, 2004; Worcester & Coe, 2008).  Normal patients 
excrete 100-250 mg of calcium per day depending on the diet of the patient.  
These increased levels of excretion can cause calcium based stones to arise.  
Although calcium oxalate stones accounts for 80% of stone formers, calcium 
phosphate stone incidences are generally also a small component of calcium 
oxalate stone formation and the incidences are accounted in only 5% of kidney 
stone forming patients. 
 Most uric acid stone formers either have gout or have a high protein diet 
paired up with low fluid intake and makes up 9% of stone formers.  There is a  
high output of uric acid in these patients and this is either caused by the over 
production of endogenous uric acid, which occurs in medical conditions such as 
gout when uric acid cannot be properly metabolized, or there is a high dietary 
intake of purine-rich foods (Arumuham & Bycroft, 2016).  The high levels of uric 
acid in the urine are insoluble in the concomitant acidic urine (pH level ≤ 5.5) that 
these patients excrete.  Due to this insolubility, uric acid stone formation can 
arise.    
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Struvite stones, on the other hand, are observed in only 8% of stone 
formation cases and are potentiated by the bacterial infection of the Proteus or 
Klebsiella or Providencia species that hydrolyzes urea to ammonium (Goel & 
Wasserstein, 2012; Khan et al., 2016).  The presence of ammonium raises the 
urine pH from neutral to alkaline values.  The precipitation of struvite occurs in 
urine with these alkalinized conditions.  Struvite stone formation can grow at a 
rapid rate into large stones. 
 
Cystinuria is an Inherited Kidney Stone Disease 
 
Cystine based stones are the least prevalent form of stones and make up 
only 1% of stone incidences.  This type of stone case is usually the result of 
cystinuria, which is a genetically inherited kidney stone disease, caused by 
mutations in either or both SLC3A1 and SLC7A9 genes.  These mutations 
specifically impair the heterodimeric cystine/dibasic amino acid transporters in 
epithelial proximal tubular cells of kidney nephrons (Mattoo & Goldfarb, 2008) 
(Fig. 2A).  These impaired transporters lead to the oversaturation of cystine in the 
urine due to the lack of cystine reabsorption (Fig. 2B).  Cystine is not soluble at 
the physiological pH of urine and this is the cause of cystine urolithiasis in 
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Fig. 2 – Cystine reabsorption and the cystine transporter in normal patients and 
cystinuric patients.  The cystine transporter is a heterodimer of two subunits 
encoded by the genes SLC3A1 and SLC7A9 and is expressed on proximal 
epithelial cells.  (A) In a normal patient, cystine is shuttled across the cystine 
transporter and is broken down into two cysteines.  The cyteines are reabsorbed 
back into the body via the blood.  (B) In cystinuric patients, the cystine 
transporter is defected due to a mutation in either the SLC3A1 or SLC7A9 genes.  
Thus, cystine cannot be broken down and is excreted via urine therefore there are 
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Patients with cystinuria typically form their first kidney stone in the first 
two decades of their lives and continue to have recurrent stone formation, 
affecting their quality of life (Lee, Sahota, Ward, & Goldfarb, 2015; Varda et al., 
2016).  Due to the high rate of cystine stone formation, patients are required to 
have surgical interventions along with their oral therapeutics.  Extracorporeal 
shock wave lithotripsy (SWL) is a minimally invasive way to surgically remove 
kidney stones by using high-energy acoustic waves to travel through the body to 
fragment kidney stones into smaller pieces that will be able to pass through the 
urinary tract.  This is the preferred method of stone removal for most of the stone 
cases previously discussed.  However, SWL isn’t always the standard of stone 
removal for cystine based stones.  Although SWL can be an effective treatment 
for cystine based stones, the composition of these types of stones are generally 
resistant to the acoustic waves and are not easily fragmented. Thus, multiple SWL 
treatments are necessary in order to fully fragment cystine stones (Claes & 
Jackson, 2012; Varda et al., 2016).  The gold standard of care for cystine stone 
removal is percutaneous nephrolithotomy (PCNL), in which an endoscope is 
percutaneously directed through the skin, muscle, and fat into the kidney for stone 
removal and lithotripsy.   
 
Treatment Options for Cystinuria are Limited 
 
Patients with cystinuria excrete 300-400mg/L of cystine per day when 
normal patients only excrete 30 mg/L of cystine on a daily basis (Claes & 
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Jackson, 2012).   In order to decrease this urine cystine concentration, patients are 
recommended to drink 3 to 4 L of water/day.  With this method, a large 
consumption of fluid is necessary around the clock in order to keep the urine 
cystine concentration diluted.  However, many patients find it difficult to maintain 
this method of treatment.   
In the 1960s, Dent et al. observed cystine solubility to be pH dependent 
and this proposed another way to target cystine urine concentration other than 
increasing fluid intake.  Urinary pH at 7.5 or above increases cystine solubility 
(Goel & Wasserstein, 2012).  Thus, urinary alkalinizing agents such as potassium 
citrate, sodium citrate, and sodium bicarbonate are another form of treatment for 
cystinurics.  Potassium citrate (KCIT) is the first line of alkalinizing agent that is 
often prescribed for patients and is also part of the standard of care for all kidney 
stone patients.  For cystinuria, KCIT is the preferred form of treatment as 
compared to sodium citrate due to sodium’s ability to increase cystine excretion in 
the urine.  Although KCIT is a commonly used form of treatment for cystinuria 
and other stone models, there is currently no knowledge on this treatment’s effect 
on stone growth.  It is important to establish an understanding since KCIT is a 
widely used therapeutic for many kidney stone models. 
Another method of increasing cystine solubility would be the use of 
pharmacological cystine-binding thiol medications.  D-penicillamine and 
tiopronin (TIO) are two commonly used thiol drugs.  The mechanism of how 
these drugs work is that they reduce the disulfide bond of cystine and the drug 
itself binds to one of the cysteine to make a drug-cystine complex.  This complex 
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is presumably 50 times more soluble in urine than cystine on its own (Dolin, 
Asplin, Flagel, Grasso, & Goldfarb, 2005; Joly et al., 1999; Mattoo & Goldfarb, 
2008).  However, side effects of the thiol medications range from change in taste 
perception, rashes, fever, and proteinuria (Claes & Jackson, 2012; Halperin, 
Thier, & Rosenberg, 1981; Mattoo & Goldfarb, 2008).  About 50% of patients 
experience side effects and long term therapy may lead to vitamin B6 deficiency, 
especially in those that are prescribed D-penicillamine.  Thus, vitamin B6 
supplements may also be prescribed in combination with the previously discussed 
treatments for patients that are using that particular thiol drug. (Biyani & 
Cartledge, 2006).  Due to the adverse effects of D-penicillamine, TIO is the 
preferred form of treatment in the United States due to its lessened side effects 
and is more well-tolerated in patients (Claes & Jackson, 2012; Halperin et al., 
1981; Joly et al., 1999; Mattoo & Goldfarb, 2008). Regardless of these lessened 
side effects of TIO, this drug can still have significant adverse effects on patients 
and this can lead to the discontinuation of usage. 
  The   goal of these limited amounts of therapeutics available for patients 
mostly targets the oversaturation of cystine present in the urine to control or 
inhibit stone formation. It is clinically successful when the cystine urine 
concentration is less than 300mg/L, but only 15% of patients successfully achieve 
lower cystine concentration in their urine due to the inefficiency of these 





α Lipoic Acid as a Cystine Stone Inhibitor in the Mouse 
 
 α lipoic acid (LA) is commonly known as a thiol antioxidant of the 
organosulfur compounds family that was discovered as an effective stone 
inhibitor by our lab (Zee et al., 2017).  As a therapeutic, LA was an effective 
inhibitor and preventer of cystine stone growth compared to control groups that 
were not administered the treatment in the Slc3a1-/- mouse model.  Here, we 
repeated previous experiments and saw similar results of LA’s ability to be an 
effective stone inhibitor and preventer.   
 On the other hand, as an antioxidant, LA play a role in the antioxidant 
response element (ARE) pathway against oxidative stress and various studies 
have shown the organosulfur compounds family had shown to upregulate Nrf2 
activation (Cui et al., 2012; Lii et al., 2010).  Nrf2 is a transcription factor 
regulating ARE-mediated genes. We hypothesized the Nrf2 pathway to be the 
mechanism in which LA was working through in order to induce stone inhibition 
and prevention by increasing Nrf2 nuclear translocation and cellular cystine 
utilization in order to inhibit cystine stone growth (Han et al., 1997; Suh et al., 
2004). 
 Thus, one of the aims of our study focused on determining whether LA 
was working through the Nrf2 pathway and observe the effects of TIO and KCIT 
as a therapeutic for inhibiting stone growth and accumulation.  In our study, we 
used the Slc3a1-/- mouse model which exhibit many symptoms similar to its 
human cystinuric counter partner and develop cystine urolithiasis.  The micro-
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computerized tomography scanner (µCT) was utilized to track stone growth and 
























METHODS AND MATERIALS 
 
Mouse Model 
All procedures and protocols were approved by the Institutional Animal Care and 
Use Committee of the Buck Institute for Research on Aging.  The mouse model 
used was the Slc3a1-/- mouse with an A129 and C57Bl/J6 mixed background.  
This model mimics all the symptoms human cystinuric patients present with the 
oversaturation of cystine in urine and the formation of cystine stones (Ercolani et 
al., 2010).  Stone formation generally began around 2-3 months old.  Only male 
mice were experimented on.  Female mice do not generally form stones and are 
excluded from this study.   Mice were kept in 12 hour light and 12 hour dark cycle 
at 24C and had free access to food. An average number of 4 to 6 males are used 
for each treatment group. 
 
Drug Treatments 
A solution of potassium citrate tribasic monohydrate (Sigma Aldrich, St. Louis, 
MO) was mixed, changed, and weighed on a weekly basis to ensure the efficiency 
of the drug and measure whether or not the mice were drinking the solutions.  The 
different dosages of 0.5%, 2%, and 4% KCIT solution were decided on previous 
KCIT studies on rat and other mouse models of other kidney stone diseases 
(Cebotaru et al., 2005; Krieger et al., 2015).  The two other dosages, 1% and 1.5% 
KCIT, were decided later in the study as two possible effective dosages due to 
side effects of the 2% and 4% KCIT dosages.  Mice were fed chow supplemented 
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with 0.25% LA or 0.5% LA or 1% tiopronin (Envigo, Huntingdon, United 
Kingdom).  The control mice received normal water and chow.  All mice involved 




Fresh urine was collected every 2 to 3 days.  Mice were placed on cardboards 
covered with plastic wrap.  Any collectable amounts of urine (20+ µL) present on 
the plastic wrap were collected immediately into Eppendorf tubes. 
 
pH Reading 
The Jenco 6230 pH meter (Jenco, San Diego, CA) was used to ensure pH 
difference between the samples soon after the urine collections. 
 
Micro-Computed Tomography (µCT) 
The µCT scanner (SkyScan 1176, Bruker, Belgium) is a noninvasive method used 
for to detect and to track the rate of stone growth.   All mice received the general 
anesthesia of 2 to 3% isoflourane before and during the scans and were placed in 
a supine position.  The scanner was set at these following settings: Resolution = 
standard, image pixel size = 1000 x 668, averaging frames = 2, filter = AL 0.5 
mm, X-ray voltage = 50 kV, anode current = 500 µA, rotation = 0.7, and exposure 
time 4 minutes.  Scans were performed weekly to detect, track, and measure the 






Scans were reconstructed as cross-sectional three dimensional (3D) images with 
the use of the software, NRecon (NRecon v1.6.9.8, Bruker-MircoCT, Belgium).  
The dynamic range on this program was set to -0.002 to 0.08 to minimize the 
background noise and ensure the consistency between the individual mouse scans.  
The reconstructed 3D images were then exported to the image analysis software, 
CT Analysis (CTAn v1.14, Bruker-MicroCT, Belgium).  A threshold between 70 
to 120 was chosen to obtain better contrast between the bladder wall and stones.  
We used the circular region of interests to focus specifically on the bladder region 
of these 3D images to detect and calculate the measurements of the amount of 
stones present on a weekly basis. 
  
Statistical Analysis 
Littermate mice were randomly assigned to a treatment or control group for each 
experiment.  Means and standard errors were calculated in each treatment and 
control group.  Two-sided Student’s t-tests were used to determine statistical 










 Cystinuria is a genetic disorder that causes the lack of cystine reuptake. 
The two genes that play a role in this disorder is SLC3A1 or SLC7A9.  When 
either of these genes is mutated, the cystine transporters expressed on the 
proximal epithelial cells are defected.  This deficiency leads to the lack of cystine 
reabsorption by the body and cystine is excreted in elevated levels through urine 
instead. The presence of excessive cystine in the urine presents a problem due to 
cystine’s lack of solubility in the bodily fluid.  Current medical therapeutics such 
as tiopronin or D-penicillamine target cystine solubility, but is often an inefficient 
preventative strategy, leaving patients with limited therapeutic options.  Thus, we 
observed tiopronin’s effect on stone formation since it is the preferred form of 
thiol treatment in the United States due to its lessened adverse effects on patients 
(Matoo & Goldfarb, 2008).  The Slc3a1-/- mouse model we utilized in our 
experiments were administered TIO at 2-3 months of age after they have already 
started to form stones in order to observe TIO’s inhibitory effects on cysteine 
stone growth (Fig. 3A).  The results suggest there was a significant decrease on 
the rate of stone growth when we compare the TIO treated group to the control 
group.    In order to observe TIO as a preventative measure, the drug was 
administered to younger mice around 1-2 months of age that had not yet formed 
stones or had very little stone accumulation present in their bladders (Fig. 3B).  
Our results indicate that although TIO was able to significantly decrease the rate 








In addition to observing tiopronin and its capabilities, KCIT’s possible 
ability to inhibit stone formation was also looked into as well.  Urinary pH is 
known to affect the solubility of cystine, thus urine alkalinizing agents such as 
KCIT is a commonly used mean of alkalinizing urinary pH as a standard of care 






























































Fig. 3 –TIO effects on stones as an intervening and preventative treatment on 
stone growth.  (A) 2-3 month Slc3a1-/- male old mice were administered normal 
(CONT) (n=8) chow and 1% TIO supplemented chow (n=9.  Rates of stone 
accumulation were expressed as means ± SEM.  (B) 1-2 month old male mice 
were administered CONT chow (n=9) and TIO supplemented food (n=9) and stone 
volume accumulated was tracked for 3 months.  Stone volumes were expressed as 
means ± SEM.   
 
p value = 0.05 
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very little known about this alkalinizing agent and its capabilities in inhibiting the 
rate of stone formation.  In our study, we want to use the highest effective dosage 
to look at the effects of KCIT on stone formation.   
0.5%, 2.0%, and 4% KCIT solutions were administered to mice.  Within 
the first week after the initial administration of the KCIT solution, the groups 
ingesting both the 2.0% and 4.0% KCIT solution were observed to have 
undergone either tremendous amounts of stress and were euthanized or were 
found dead.  We immediately stopped the administration of the two highest 
dosages and began the administration of 1% and 1.5% KCIT solutions instead and 
with careful observations.  Urine was collected on a 2-3 day basis and pH was 
measured by a pH meter.  We discovered the 1.5% KCIT group eventually 
developed complications similar to the 2% KCIT and 4% KCIT groups, thus we 
discontinued the usage of it immediately.  This action left 1% KCIT as our final 
and highest dosage.   
We looked into the effects of KCIT on stone growth with a range dosages 
consisting of 0.25% KCIT, 0.5% KCIT, and 1% KCIT (Fig. 4A).  Of the three 
various dosages we administered, 0.5% KCIT was the most efficient at inhibiting 
stone growth.  Meanwhile the 0.25% KCIT and 1% KCIT had minimal to no 
inhibitory effect on the rate of stone growth.   In addition to tracking these 
dosages’ effects on stone growth, we also kept track on their effects on weight 
(Fig. 4B).  All weights of all the groups were similar and within a normal range.  
In addition, the effect of KCIT on urinary pH was also observed (Fig.4C).  Our 
results indicated that we were not successful in alkalinizing the urinary pH of our 
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mice.  There were no statistical significance between the urinary pH levels of the 
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Fig. 4 – Effect of varying dosages of KCIT on urinary stone formation, 
weight, and urinary pH on Slc3a1-/- mice.  (A) 2-3 month old male Slc3a1-/- 
mice were administered three dosages ranging from 0.25% KCIT (n=5), 
0.5% KCIT (n=5), 1% KCIT (n=4), and CONT water (n=5) for over a 
month; a total of 6 µCT scans were conducted.  Rates of stone growth are 
expressed as mean ± SEM.  (B) Weights of mice in the duration of the drug 
treatments.  Weights are expressed as mean ± SEM.  (C) 2 month old male 
Slc3a1-/- mice were administered normal water, 0.5% potassium citrate 
(KCIT), or 1% KCIT solution for 2 months.  Urine samples were collected 
on a 3-4 day basis.  pH of urine samples was measured by a pH meter. The 













We recently reported the thiol antioxidant, LA, to be a successful inhibitor 
and preventer of cystine stone formation in the Slc3a1-/- mouse mice (Zee et al, 
2017).  Here, we further confirm LA as an effective treatment of cystine stone 
























drug, we administered the drug to mice around 2 to 3 months of age and tracked 
their rate of stone growth for 35 days (Fig. 5A).  The group on LA treatment had a 
significantly lower rate of stone growth when compared to the control group.  
These results suggested that LA was a strong inhibiting treatment.  In addition to 
observing LA as an inhibiting stone growth treatment, we also observed this 
treatment’s capabilities as a preventative treatment.  We administered LA to 
young mice that have not yet started to form stones or haven’t accumulated much 
yet (Fig. 5B).  Our results indicate LA to be an effective stone preventer of stone 
formation. 
 Since LA’s mechanism of inhibiting stone formation is unknown, there are 
possibilities of it acting as a urine alkalinizing agent such as KCIT.  Thus, urine 
from LA treated mice was collected to observe the possible alkalinizing effects 
LA may have on urinary pH (Fig. 5C).  The results suggest that LA did not 
alkalinize the urinary pH of the mice during the administration of this drug.  The 
possible mechanism in which LA may be working through in order to inhibit 
stone formation and prevention was not through alkalinizing urine. In addition, 
we also kept track of the weights of the mice in the duration of the LA 
administration to ensure the mice’s weights were within a normal range and our 
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Fig. 5 – LA as a treatment of cystine based stones.  (A)  2-3 month old mice 
were administered CONT food (n=8) and 0.5% LA supplemented chow (n=5) 
for over one month; a total of a total of 7 µCT scans were conducted.  Results 
are expressed as means ± SEM.  (B) CONT food (n=9) and LA supplemented 
food (n=9) was given to mice 1-2 month old mice and stone accumulation was 
tracked for 6 months.  Results are expressed as mean ± SEM.  (C) Urine 
samples were collected on a 3-4 day basis and pH values were measured via pH 
meter.  Readings are expressed as mean ± SEM (n=5 per condition).  (D) 
Weights of mice in the duration of the drug treatment.  Weights are expressed 
as mean ± SEM (n=5 per condition).  Two-tailed Student’s tests were used to 





 The mechanism in which LA worked through in order to inhibit stone 
growth was unknown to us.  As a known target of LA, the Nrf2 pathway was 
hypothesized to be the mechanism that LA worked through to inhibit stone 
growth.  Nrf2 is an oxidative stress induced pathway that directly transcribes 
antioxidant and detoxifying enzymes for cellular defense (Suh et al, 2004; Shi et 
al, 2016; Shay et a, 2009).  There are various studies that have shown 
organosulfur compounds to increase upregulation of Nrf2 activation (Cui et al., 
2012; Lii et al., 2010).  In the Slc3a1-/-; Nrf2+/+ mouse model, our results indicate 
LA was able to successfully inhibit stone growth as we had previously see when 
compared to the control group (Fig. 6A).  We knocked out Nrf2 in our Slc3a1-/- 
mice to create a double knockout mouse model in order to observe the possible 
role the Nrf2 pathway had in LA’s ability to inhibit stone growth (Fig. 6B).  The 
results indicate that LA was still successful in inhibiting the rate of stone growth 
despite the knockout of Nrf2 in the Slc3a1-/- mouse.  These results suggest that 









 Since urine alkalinizing agents are commonly used as a standard of care 
for patients (Goel and Wasserstein, 2012), we therefore addressed whether the 
usage of KCIT combined with LA would have an antagonistic, additive, or 



















































Slc3a1-/-; Nrf2-/- Mice on LA Treatment
A  
B  
Fig 6 – Nrf2 knockdown had no effect on LA’s ability to inhibit stone growth.  
(A) 2 month old Slc3a1-/-; Nrf2+/+ mice on LA treatment for 2 months; a total 
of a total of 11 µCT scans were conducted. Rate of stone growth are expressed 
as means ± SEM (n= 4 per condition).  (B) 2 month old Slc3a1-/-; Nrf2-/- mice 
on LA treatment for 2 months.  Rate of stone growth are expressed as means ± 
SEM (n= 7 per condition).  Two-tailed Student’s tests were used to determine 
statistical significance. 
p value = 1.04 E-08 
 
p value  = 9.90 E-05 
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up with a high dosage of KCIT.  Our results showed that both the low dosage of 
LA and high dosage of KCIT was able to independently decrease the rate of stone 
growth (Fig. 7A).  However, when we administer the two drugs in conjunction, 
there seemed to be no antagonistic, additive, or synergistic effects of the two. 
There are no significant differences between the different drug treatment 
conditions.  The effects of the drugs on the rate of stone growth was also mirrored 














Fig. 7 – Effect of KCIT and 0.25% LA on stone growth and accumulation. 
(A) Average stone volume accumulation and (B) average rate of stone 
growth was tracked by the µCT scanner for 3 months; a total of a total of 9 
µCT scans were conducted.  The data are presented as means ± SEM (n=6 








































































  Cystinuria is an autosomal recessive genetic disease that causes the lack of 
cysteine reabsorption through the mutation of one of the genes, SLC3A1 or 
SLC7A9.  The mutation of either one of these two genes causes a defect in the 
cystine transporter present in epithelial proximal tubular cells and leads to the lack 
of cystine reabsorption.  Since the body cannot reuptake cysteine due to the defect 
of this transporter, cystine is excreted in excess via urine instead.  The 
oversaturation of cystine present in the urine eventually leads to cystine stone 
formation.  There are currently no known pharmacotherapies that have been 
shown to successfully inhibit cystine stone formation although drugs such as D-
penicillamine and tiopronin are commonly used (Claes & Jackson, 2012; Mattoo 
& Goldfarb, 2008).  Aside from these thiol therapeutics, patients do not have 
much treatment options aside from using the urine alkalinizing agent and 
increasing fluid intake as methods to decrease aggressive cystine stone formation. 
The conservative methods of treating cystinuria generally consist of the 
combination of increased consumption of fluids and using alkalinizing agents to 
target cystine urine concentration.  These two methods are ineffective and the 
addition of thiol pharmaceutical drugs such as D-penicillamine and TIO are 
necessary to treat cystinuric patients.  The use of D-penicillamine as a treatment 
began in 1963 when the drug was observed to have a significant effect on cystine 
solubility in patients of this genetic disease.  Although the drug has been shown to 
have tremendous side effects on patients that includes rashes, fever, proteinuria, 
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and change in the perception of taste along with vitamin B6 deficiency since the 
1960’s, patients are still prescribed this drug treatment (Claes & Jackson, 2012; 
Crawhall, Scowen, & Watts, 1963; Halperin et al., 1981; Mattoo & Goldfarb, 
2008).   
Other forms of thiol therapies have been created since the introduction of 
D-penicillamine with the hope that they will have the same effect on cystine 
solubility with lessened side effects effects.  Captopril and bucillamine are other 
thiol pharmacotherapies available aside from the previously discussed D-
penicillamine and TIO.  Unfortunately, there are few studies focused on these two 
drugs and the effectiveness of them.  Captopril was shown to decrease cystine 
excretion in cystinuric patients, but the drug has been shown to have many 
inconsistencies and was suggested to be used for patients that cannot control their 
cystine stone formation with the use of D-penicillamine or tiopronin (Chow & 
Streem, 1996; Cohen, Streem, & Hall, 1995; Halperin et al., 1981; Sloand & Izzo, 
1987).  Meanwhile, bucillamine had only been previously available to patients in 
South Korea and Japan (Biyani & Cartledge, 2006).  Thus, there a few available 
clinical studies in the United States that observes the efficacy of bucillamine as a 
new method of treatment.   
TIO is currently the main choice of thiol treatment aside from D-
penicillamine in the U.S. due to both the drugs’ similar mechanism of action.  
Due to this similar mechanism of action, TIO also have a similar side effect 
profile as compared to D-penicillamine but this drug is better tolerated by 
patients.  Both of these thiol drugs had been shown to be effective in decreasing 
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the rate of stone formation in patients, but many were still considered at a high 
risk of stone reoccurrence (Chow & Streem, 1996).  Our results mirrored what has 
been seen in regards to TIO’s modest capability to intervene in the rate of growth 
in our mice.  Just as Chow and Streem had observed, our results indicate that TIO 
was unable to successfully prevent stone formation unlike LA as a treatment. 
Zee et al reported the oral administration of the thiol antioxidant, LA, as 
an effective cystine stone inhibitor and preventer in the Slc3a1-/- mouse model as 
compared to untreated Slc3a1-/- mice.  In this study, LA was identified as an 
effective inhibitor of stone growth through a drug screen consisting of various 
compounds that have been shown to activate the ARE pathway to promote 
glutathione synthesis and increase cellular cysteine uptake.   Our results further 
confirmed the report of LA’s abilities to act as an efficient inhibitor and preventer 
of cystine stone formation.  LA is a known thiol antioxidant that has been shown 
to increase Nrf2, a transcription factor that mediates ARE mediated genes, 
translocation and increase cellular cysteine utilization (Cui et al., 2012; Lii et al., 
2010). Due to these previously shown effects of LA, Nrf2 was the pathway we 
hypothesized LA worked through in order to induce stone inhibition and 
prevention in our mice.  However, our results indicated that LA worked 
independently of the Nrf2 pathway to inhibit stone formation in our Slc3a1-/-; 
Nrf2-/- mice.  The effects of LA treatment on the rate of stone growth in Slc3a1-/-; 
Nrf2-/- mice were not significantly different compared to Slc3a1-/- mice. 
Alkalinizing agents is a standard of care for all cystinuric patients in order 
to increase urinary pH and increase cystine solubility (Dent, Friedman, Green, & 
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Watson, 1965; Joly et al., 1999; Mattoo & Goldfarb, 2008).  KCIT is the preferred 
form of alkalinizing agents for patients over others forms.  Citrate treatments such 
as sodium citrate increase the cystine excretion in patients and this is not ideal in 
the clinical setting.  The increased excretion of cystine in the urine may have an 
impact on the rate of stone reoccurrence in cystinuric patients thus sodium citrate 
is a second line of treatment if necessary.    However, the usage of KCIT and 
increasing liquid intake are generally not enough to tackle stone formation and 
prevention alone.  Thus, the addition of thiol drugs is necessary (Barbey et al., 
2000; Dolin et al., 2005).  When we observe KCIT as a treatment without the 
addition of increased fluid intake or thiol drugs, the treatment was shown to have 
varying effects on stone formation and urinary pH.  This may be due to various 
factors.  In regards to urinary pH, a factor as to why KCIT was not successful in 
alkalinizing the urine of our mice may be due to KCIT’s varying effects on 
urinary pH in the clinical setting and our results may be mirroring what is 
commonly seen in the clinic (Asplin & Asplin, 2013; Barbey et al., 2000).  Or, 
another possibility is that KCIT may be working through another mean of action 
that is independent of urinary pH such as through its metabolites in order to 
increase cystine solubility and inhibit stone formation.   
Some inconsistencies could be due to how KCIT was administered to our 
mice since the method of drug administration plays a crucial role in any 
experimental design (Turner, Brabb, Pekow, & Vasbinder, 2011).  KCIT was 
given to the mice in their drinking water instead of other methods such as gavage 
or a KCIT supplemented diet to mirror clinical settings (Joly et al., 1999; Mattoo 
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& Goldfarb, 2008).  It was observed that the water levels of the 1% KCIT solution 
were slightly higher than the other dosage solutions when water bottles were 
being changed out on a weekly basis.  This could have been an indication that 
mice under the higher dosages of KCIT may have not been drinking as much 
water as mice on the lower dosages of KCIT or control water.  These differences 
in water levels were not significant and did not raise much of a concern.  
However, we have taken into consideration that when a drug is administered 
through a solution, we cannot account for the proper dosage the mice are 
ingesting.   In order to ensure the mice ingest the proper dosage in future 
experiments, gavage or the usage of a supplemented diet will be taken into 
consideration. 
The treatments for cystinurics generally consist of the combinations of 
high fluid intake, urine alkalinizing agents, and thiol drugs.  Although thiol drugs 
can significantly decrease stone formation and increase cystine solubility, there is 
still a high risk of rapid stone reoccurrence in patients (Barbey et al., 2000; Chow 
& Streem, 1996; Dolin et al., 2005; Khan et al., 2016).  Thus, many patients are 
required to have close surveillance from physicians such as frequent visits to the 
clinic to perform radiological imaging and 24 hour urine collections.  As a method 
to target urine cystine solubility, KCIT is the standard of care for all cystinuric 
patients. When LA is administered in the clinical setting, this new drug treatment 
will be administered in combination with KCIT.  Both KCIT and LA were 
administered in conjunction to observe the possible adverse, additive, or 
synergistic effects the two drugs have on one another.   There are many questions 
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that can arise in regards to why a high dosage of KCIT was paired with a medium 
dosage of LA.  A high dosage of KCIT was chosen for the combination  
experiment due to our interest in mirroring clinical settings.  For the clinical 
setting, patients will be administered the highest tolerable dosage for their specific 
body mass indexes.  As discussed before, the 1% KCIT was discovered to be the 
most tolerable dosage for our mice without any detrimental side effects through a 
dosage experiment with the higher dosages of 1.5% KCIT, 2% KCIT, and 4% 
KCIT.  There are possibilities that this highest tolerable dosage of KCIT may be 
masking the possible additive or synergistic effects of the administration of KCIT 
and LA in conjunction.  For future experiments, we shall consider administering a 
lower dosage of KCIT. 
For future directions, we plan to look into the mechanism of how LA 
inhibits the rate of stone growth in our mice.  In this particular study, we showed 
that LA worked independently of alkalinizing urinary pH and the Nrf2 pathway to 
inhibit stone growth and formation.  Thus, the mechanism of LA to induce stone 
inhibition and prevention is still unclear.  We currently hypothesize LA to be 
working through its metabolites to increase cystine solubility in the urine (Zee et 
al., 2017).   
In addition, there is an interest to start observing the effects of a LA 
supplemented diet on other stone models aside from cystinuria and its effects on 
stone growth and prevention.  The stone model of interest will be the calcium 
oxalate kidney stone model.  This stone disease is the most commonly diagnosed 
stone model with a prevalence of 80% of kidney stone cases (Goel & Wasserstein, 
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2012; Khan et al., 2016).  As discussed previously, KCIT is a standard of care for 
cystinurics due to its observed ability to increase cystine solubility through the 
means of increasing urinary pH.   This alkalinizing agent is also a standard of care 
for calcium stone formers because of citrate’s ability to bind to calcium and 
reduce the amount of calcium that is available to bind with oxalate (Coe et al., 
2016; Khan et al., 2016).  In our future studies, we plan to observe the effects and 
efficiency of KCIT along with LA in the context of the calcium oxalate kidney 
stone model just as we had previously done with the cystinuric kidney stone 
model. 
We will use the primary hypoxaluria type 1 disease model to observe 
KCIT and LA’s effects on calcium oxalate stone formation.  Primary hypoxaluria 
is a genetic disorder characterized by the mutation of the alanine-glyoxylate 
aminotransferase in the liver (Dutta et al., 2016).  When this aminotransferase is 
defected, oxalate is overproduced by the liver and is present in the kidney and 
urine in abnormally high amounts.  The high presence of oxalate leads to the 
crystallization and eventually formation of calcium oxalate based kidney stones.  
Although this disorder is hereditary, we want to use a model that will ensure the 
formation of calcium oxalate stones.  Methods such as the administration of 
ethylene glycol to induce hyperoxaluria and hypercalciuria in mice may be 
inefficient and may take months before the initial formation of calcium based 
bladder stones.  Thus, the primary hypoxaluria type 1 disease model will be our 
calcium oxalate stone model of interest and we will observe the effects of KCIT 





 In summary, our results showed that TIO had a modest effect both on 
stone growth inhibition and did not successfully prevent stone formation.  In our 
study, the varying effects on urinary pH and stone growth with KCIT were 
consistent with what was seen in the clinical setting.  We further confirm the 
efficiency of LA as a stone growth inhibitor and stone preventor (Fig. 1 and Fig. 
3).  We hypothesized the Nrf2 pathway to be the mechanism in which LA worked 
through in order ot inhibit the rate of stone growth. When LA was administered to 
the Slc3a1-/- ; Nrf2 -/- mouse model, our results indicated that Nrf2 was not the 
pathway LA worked through in order to inhibit stone growth.    When we pair up 
KCIT with LA, there seemed to be no adverse effect on LA’s ability to inhibit the 
rate of stone growth.  This is an important observation for clinical settings when 
both KCIT and LA will be administered in combination with one another.  Our 
research suggsted that LA is a new possible therapeutic for patients with 
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